The short- and long-term effect of duloxetine on painful physical symptoms in patients with generalized anxiety disorder: Results from three clinical trials

Journal of Anxiety Disorders

Volumn 23, Issue 8, 2009, Pages 1064-1071

  Beesdo, Katja ^a   Hartford, James ^b   Russell, James ^c   Spann, Melissa ^c   Ball, Susan ^c,d   Wittchen, Hans Ulrich ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b Community Research Group ^*  (United States)

^c ELI LILLY AND COMPANY   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Duloxetine; Generalized anxiety disorder; Pain; Relapse prevention; Serotonin and norepinephrine reuptake inhibitor

Indexed keywords

DULOXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR;

ADULT; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PAIN; PAIN ASSESSMENT; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SHORT COURSE THERAPY; SHOULDER PAIN; SINGLE BLIND PROCEDURE; VISUAL ANALOG SCALE;

ADULT; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SOMATOFORM DISORDERS; THIOPHENES; TREATMENT OUTCOME;

EID: 70349764340     PISSN: 08876185     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.janxdis.2009.07.008     Document Type: Article

References (48)

1. Ansseau M., Dierick M., Buntinkx F., Cnockaert P., De Smedt J., Van Den Haute M., et al. High prevalence of mental disorders in primary care. Journal of Affective Disorders 78 (2004) 49-55
2. Arnold L.M., Lu Y., Crofford L.J., Wohlreich M., Detke M.J., Iyengar S., et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis and Rheumatism 50 (2004) 2974-2984
3. Arnold L.M., Rosen A., Pritchett Y.L., D'Souza D.N., Goldstein D.J., Iyengar S., et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 119 (2005) 5-15
4. Beesdo K., Hoyer J., Jacobi F., Low N.C., Höfler M., and Wittchen H.U. Association between generalized anxiety levels and pain in a community sample: evidence for diagnostic specificity. Journal of Anxiety Disorders 23 (2009) 684-693
5. Beesdo, K., Jacobi, F., Hoyer, J., Low, N. C. P., Höfler, M., & Wittchen, H. U. (2009). Pain associated with specific anxiety and depressive disorders in a nationally representative population sample. Social Psychiatry and Psychiatric Epidemiology, doi:10.1007/s00127-009-0045-1 (ePub ahead of print).
6. Beesdo, K., Pine, D. S., Lieb, R., & Wittchen, H. U. (in press). Similarities and differences in incidence and risk patterns of anxiety and depressive disorders: the position of generalized anxiety disorder. Archives of General Psychiatry.
7. Collins S.L., Moore R.A., and McQuay H.J. The visual analogue pain intensity scale: what is moderate pain in millimetres?. Pain 72 (1997) 95-97
8. Davidson J.R., Wittchen H.U., Llorca P.M., Erickson J., Detke M., Ball S.G., et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. European Neuropsychopharmacology 18 (2008) 673-681
9. DeLoach L.J., Higgins M.S., Caplan A.B., and Stiff J.L. The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesthesia Analgesia 86 (1998) 102-106
10. Demyttenaere K., Bruffaerts R., Lee S., Posada-Villa J., Kovess V., Angermeyer M.C., et al. Mental disorders among persons with chronic back or neck pain: results from the World Mental Health Surveys. Pain 129 (2007) 332-342
11. Farrar J.T., Young Jr. J.P., LaMoreaux L., Werth J.L., and Poole R.M. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94 (2001) 149-158
12. Fröhlich C., Jacobi F., and Wittchen H.U. DSM-IV pain disorder in the general population. An exploration of the structure and threshold of medically unexplained pain symptoms. European Archives of Psychiatry and Clinical Neuroscience 256 (2006) 187-196
13. Goldstein D.J., Lu Y., Detke M.J., Hudson J., Iyengar S., and Demitrack M.A. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 45 (2004) 17-28
14. Goldstein D.J., Lu Y., Detke M.J., Lee T.C., and Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 116 (2005) 109-118
15. Gureje O., Von Korff M., Kola L., Demyttenaere K., He Y., Posada-Villa J., et al. The relation between multiple pains and mental disorders: results from the World Mental Health Surveys. Pain 135 (2008) 82-91
16. Guy W. The clinician global severity and impression scales. In ECDEU assessment manual for psychopharmacology [76-338] (1976), US Department of Health, Education, and Welfare, Rockville, MD pp. 218-222
17. Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 32 (1959) 50-55
18. Hartford J.T., Endicott J., Kornstein S.G., Allgulander C., Wohlreich M.M., Russell J.M., et al. Implications of pain in generalized anxiety disorder: efficacy of duloxetine. Primary Care Companion to The Journal of Clinical Psychiatry 10 (2008) 197-204
19. Hartford J., Kornstein S., Liebowitz M., Pigott T., Russell J., Detke M., et al. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. International Clinical Psychopharmacology 22 (2007) 167-174
20. Hedges L.V., and Olkin I. Statistical methods for meta-analysis (1985), Academic Press, San Diego, CA
21. Iyengar S., Webster A.A., Hemrick-Luecke S.K., Xu J.Y., and Simmons R.M. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. Journal of Pharmacology and Experimental Therapeutics 311 (2004) 576-584
22. Kessler R.C., DuPont R.L., Berglund P., and Wittchen H.U. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. American Journal of Psychiatry 156 (1999) 1915-1923
23. Koponen H., Allgulander C., Erickson J., Dunayevich E., Pritchett Y., Detke M.J., et al. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Primary Care Companion to The Journal of Clinical Psychiatry 9 (2007) 100-107
24. Lieb R., Becker E.S., and Altamura A.C. The epidemiology of generalized anxiety disorder in Europe. European Neuropsychopharmacology 15 (2005) 445-452
25. Lipman R.S., and Covi L. Outpatient treatment of neurotic depression: medication and group psychotherapy. Proceedings of the Annual Meeting of the American Psychopathological Association 64 (1976) 178-218
26. McWilliams L.A., Cox B.J., and Enns M.W. Mood and anxiety disorders associated with chronic pain: an examination in a nationally representative sample. Pain 106 (2003) 127-133
27. McWilliams L.A., Goodwin R.D., and Cox B.J. Depression and anxiety associated with three pain conditions: results from a nationally representative sample. Pain 111 (2004) 77-83
28. Means-Christensen A., Roy-Byrne P.P., Sherbourne C.D., Craske M.G., and Stein M.B. Relationships among pain, anxiety and depression in primary care. Depression and Anxiety 25 (2008) 593-600
29. Nicolini H., Bakish D., Duenas H., Spann M., Erickson J., Hallberg C., et al. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial. Psychological Medicine 19 (2008) 1-10
30. Olfson M., and Gameroff M.J. Generalized anxiety disorder, somatic pain and health care costs. General Hospital Psychiatry 29 (2007) 310-316
31. Olfson M., Shea S., Feder A., Fuentes M., Nomura Y., Gameroff M., et al. Prevalence of anxiety, depression, and substance use disorders in an urban general medicine practice. Archives of Family Medicine 9 (2000) 876-883
32. Raskin A., Schulterbrandt J., Reatig N., and McKeon J.J. Replication of factors of psychopathology in interview, ward behavior and self-report ratings of hospitalized depressives. Journal of Nervous and Mental Disease 148 (1969) 87-98
33. Raskin J., Pritchett Y.L., Wang F., D'Souza D.N., Waninger A.L., Iyengar S., et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Medicine 6 (2005) 346-356
34. Ruscio A.M., Chiu W.T., Roy-Byrne P., Stang P.E., Stein D.J., Wittchen H.-U., et al. Broadening the definition of generalized anxiety disorder: effects on prevalence and associations with other disorders in the national comorbidity survey replication. Journal of Anxiety Disorders 21 (2007) 662-676
35. Russell I.J., Mease P.J., Smith T.R., Kajdasz D.K., Wohlreich M.M., Detke M.J., et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 136 (2008) 432-444
36. Russell J.M., Weisberg R., Fava M., Hartford J.T., Erickson J.S., and D'Souza D.N. Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms. Depression and Anxiety 25 (2008) E1-11
37. Rynn M., Russell J., Erickson J., Detke M.J., Ball S., Dinkel J., et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depression and Anxiety 25 (2008) 182-189
38. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 59 Suppl. 20 (1998) 22-33
39. Stein M.B. Attending to anxiety disorders in primary care. Journal of Clinical Psychiatry 64 Suppl. 15 (2003) 35-39
40. Turner E.H., Matthews A.M., Linardatos E., Tell R.A., and Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine 358 (2008) 252-260
41. Von Korff M., Crane P., Lane M., Miglioretti D.L., Simon G., Saunders K., et al. Chronic spinal pain and physical-mental comorbidity in the United States: results from the National Comorbidity Survey Replication. Pain 113 (2005) 331-339
42. Wernicke J.F., Pritchett Y.L., D'Souza D.N., Waninger A., Tran P., Iyengar S., et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 67 (2006) 1411-1420
43. Wittchen H.-U., Beesdo K., and Kessler R.C. The impact of generalized anxiety disorder. In: Nutt D.J., Rickels K., and Stein D.J. (Eds). Generalized anxiety disorder: symptomatology, pathogenesis and management (2002), Martin Dunitz, London 11-26
44. Wittchen H.U., Carter R.M., Pfister H., Montgomery S.A., and Kessler R.C. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. International Clinical Psychopharmacology 15 (2000) 319-328
45. Wittchen H.U., Kessler R.C., Beesdo K., Krause P., Hofler M., and Hoyer J. Generalized anxiety and depression in primary care: prevalence, recognition, and management. Journal of Clinical Psychiatry 63 Suppl. 8 (2002) 24-34
46. Wittchen H.U., Zhao S., Kessler R.C., and Eaton W.W. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Archives of General Psychiatry 51 (1994) 355-364
47. Wong D.T., and Bymaster F.P. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype?. Progress in Drug Research 58 (2002) 169-222
48. Zigmond A.S., and Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica 67 (1983) 361-370